logo-loader
viewFlybe Group

Britsh Airways owner IAG and easyJet seen as among possible bidders for Flybe

Flybe is in discussions with “a number of strategic operators” about a potential sale of the company

Flybe i
Flybe is reviewing its strategic options after issuing a profit warning last month

Flybe Group PLC (LON:FLYB) has announced that it is considering putting itself up for sale, leading to market speculation on possible bidders for the airline.

The airline said on Wednesday that it was in discussions with “a number of strategic operators” about a potential sale of the company as it reported a 54% drop in first-half profits to £7.4mln on a 2.4% drop in revenues to £419.2mln.

IAG seen as a potential bidder as it eyes expansion

The move comes after the company warned last month that it would post a full-year loss of £22mln due to subdued consumer demand, higher fuel costs and a weaker pound following the Brexit vote.

Now that a sale of Flybe is on the cards, the question is who would be willing to come to the rescue, given that many airlines are facing similar challenges.

Neil Wilson, chief market analyst at Markets.com, said the “usual suspects” of British Airways owner International Consolidated Airlines Group PLC (LON:IAG) and easyJet PLC (LON:EZY) were probably the “best shouts” as possible rescuers.

“Exposure to UK market may be a tad risky for others right now, although it will be a bargain,” he added.

IAG is seen as a potential candidate because the group, which also owns Aer Lingus, Vueling and Iberia, has been looking to expand. The company has had its eye on buying Norwegian Air Shuttle but it has been turned down on two takeover offers previously. 

READ: FlyBe lifted as it puts itself up for sale blaming Brexit and fuel costs for slashed profits in half year

While many analysts see the benefit in combining IAG and Norwegian, it depends on the price.

“IAG has been rebuffed twice before, so it’s unlikely to get Norwegian on the cheap. That heightens the risk of overpaying,” said George Salmon, equity analyst at Hargreaves Lansdown.

In contrast, IAG could fetch Flybe at a good price, given the budget airline’s willingness to sell and the fact that its shares have fallen almost 75% since September.

The group used to own a stake in Flybe but sold the shares in 2014, saying its holding in the airline has “never been a strategic one”.

The sale came as Flybe carried out a turnaround plan to restore its financial health. At the time, IAG said "This decision is no reflection of our view of Flybe which is making good progress with its turnaround plan. This is the right time to sell."

easyJet could swoop in to boost UK network 

If IAG hasn’t changed its mind about Flybe, easyJet may decide to swoop in with an offer to buy the company.

easyJet recently expanded its German operations with the €40mln acquisition of operations from collapsed Air Berlin last year and could also beef up its UK network of flights through the acquisition of Flybe.

Flybe has the highest number of flights at a dozen UK airports, including Aberdeen, Belfast City, Birmingham, Glasgow, Manchester and Southampton.

Having a strong presence in both the UK and the European Union is currently key for airlines operating across both sides amid concerns about the loss off flying rights in the event of a “no deal” Brexit outcome.

Stobart touted as possible contender for Flybe

Market participants have also suggested Stobart Group PLC (LON:STOB), the owner of London Southend Airport, could reconsider buying Flybe after ending takeover talks earlier this year.

Aside from a potential sale, Flybe said in Wednesday’s announcement that it was reviewing other "strategic options”, including cutting more flights to strengthen its balance sheet and preserve cash resources.

Flybe has appointed Evercore as its financial adviser to assist with its review of options to address market challenges.

Quick facts: Flybe Group

Price: 0 GBX

AIM:FLYB
Market: AIM
Market Cap: £0.00
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'The clinical benefits of Clevegen have now been demonstrated' Faron Pharma CEO

Faron Pharmaceuticals Oy's (LON:FARN) Markku Jalkanen caught up with Proactive London's Andrew Scott to discuss the recently released Matins trial update which is assessing the firm's drug Clevegen. He says feedback from the dose escalation study confirmed Clevegen has good tolerability...

3 minutes ago

4 min read